Abstract: Objective · To investigate whether intraperitoneal injection of liraglutide can improve the inflammatory state of allergic rhinitis (AR) in mice and provide new treatment options for AR. Methods · Eighteen BALB/c mice (SPF grade) were divided into three groups (control group, AR group and treatment group)random number method. The AR and treatment group were established through intraperitoneal injection of OVA and aluminum hydroxide (replacedphysiological saline in control group). And treatment group received intraperitoneal injection of liraglutide (replacedphysiological saline in control and AR groups). The changes in the numbers of sneezing and nose scratching of mice were observed after the intervention of liraglutide. The number of eosinophil infiltration, goblet cell proliferation and mucosal thickness in mice nasal mucosa were measured. Enzyme-linked immunosorbent assays were used to detect the concentrations of OVA-specific IgE (OVA-sIgE), IL-4 and IL-5 in serum of mice. Results · In control group, there were rare eosinophils and goblet cell hyperplasia. In AR group, obvious goblet cell hyperplasia, significant eosinophil infiltration and thickening mucosal were observed. The number of eosinophil, goblet cell hyperplasia, and mucosal thickness in AR group significantly increased compared with those in control group (all P<0.05). The numbers of nose scratching and sneezing in AR group were significantly higher than those in the control group (both P<0.05), and the above symptoms in treatment group were improved compared with AR group (both P<0.05). The serum concentrations of OVA-sIgE, IL-4 and IL-5 in AR group were significantly higher than those in control group (all P<0.05), and the above indicators in treatment group were lower than those in AR group (all P<0.05). Conclusion · Intraperitoneal injection of liraglutide can effectively improve the symptoms and inflammatory level of AR in mice, which may be a novel research direction in the treatment of AR.

Key words: momodel, allergic rhinitis, eosinophil, glucagon-like peptide-1